ImmunoGen, Inc. Logo

ImmunoGen, Inc.

IMU.DE

(0.8)
Stock Price

5,17 EUR

-8.89% ROA

-21.97% ROE

-19.65x PER

Market Cap.

1.250.743.313,80 EUR

13.63% DER

0% Yield

-25.41% NPM

ImmunoGen, Inc. Stock Analysis

ImmunoGen, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

ImmunoGen, Inc. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a minimal amount of debt (13%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

2 PBV

The stock's PBV ratio (2.54x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

3 ROE

The stock's ROE indicates a negative return (-21.97%) on shareholders' equity, suggesting poor financial performance.

4 ROA

The stock's ROA (-8.89%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

5 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

6 Net Profit Growth

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

7 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

8 Graham Number

The company's Graham number suggests that its stock price is overestimated, implying that it may not be a promising investment opportunity.

9 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

10 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (-21), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

ImmunoGen, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

ImmunoGen, Inc. Technical Stock Analysis
# Analysis Recommendation

ImmunoGen, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

ImmunoGen, Inc. Revenue
Year Revenue Growth
1988 800.000
1989 1.000.000 20%
1990 3.400.000 70.59%
1991 2.700.000 -25.93%
1992 1.700.000 -58.82%
1993 900.000 -88.89%
1994 500.000 -80%
1995 500.000 0%
1996 400.000 -25%
1997 600.000 33.33%
1998 3.700.000 83.78%
1999 11.180.505 66.91%
2000 4.479.363 -149.6%
2001 5.882.903 23.86%
2002 7.628.276 22.88%
2003 25.955.730 70.61%
2004 35.718.000 27.33%
2005 32.088.000 -11.31%
2006 38.212.000 16.03%
2007 40.249.000 5.06%
2008 27.988.000 -43.81%
2009 13.943.000 -100.73%
2010 19.305.000 27.78%
2011 16.357.000 -18.02%
2012 35.535.000 53.97%
2013 59.896.000 40.67%
2014 85.541.000 29.98%
2015 60.002.000 -42.56%
2017 115.447.000 48.03%
2018 53.816.000 -114.52%
2019 82.271.000 34.59%
2020 132.299.000 37.81%
2021 69.856.000 -89.39%
2022 108.782.000 35.78%
2023 453.700.000 76.02%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

ImmunoGen, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1988 0
1989 0 0%
1990 0 0%
1991 0 0%
1992 0 0%
1993 0 0%
1994 0 0%
1995 9.600.000 100%
1996 7.400.000 -29.73%
1997 6.600.000 -12.12%
1998 6.100.000 -8.2%
1999 8.878.105 31.29%
2000 15.213.164 41.64%
2001 17.694.031 14.02%
2002 23.428.854 24.48%
2003 22.224.152 -5.42%
2004 30.539.000 27.23%
2005 40.908.000 25.35%
2006 45.837.000 10.75%
2007 60.013.000 23.62%
2008 45.904.000 -30.74%
2009 50.280.000 8.7%
2010 63.453.000 20.76%
2011 69.192.000 8.29%
2012 87.073.000 20.54%
2013 106.958.000 18.59%
2014 111.768.000 4.3%
2015 148.077.000 24.52%
2017 139.739.000 -5.97%
2018 173.886.000 19.64%
2019 114.522.000 -51.84%
2020 114.592.000 0.06%
2021 151.117.000 24.17%
2022 213.370.000 29.18%
2023 190.280.000 -12.13%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

ImmunoGen, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1988 1.000.000
1989 1.400.000 28.57%
1990 1.400.000 0%
1991 18.000.000 92.22%
1992 20.200.000 10.89%
1993 4.500.000 -348.89%
1994 3.000.000 -50%
1995 1.800.000 -66.67%
1996 2.200.000 18.18%
1997 1.700.000 -29.41%
1998 1.800.000 5.56%
1999 3.063.403 41.24%
2000 4.481.802 31.65%
2001 5.403.367 17.06%
2002 5.957.469 9.3%
2003 6.631.012 10.16%
2004 8.765.000 24.35%
2005 9.898.000 11.45%
2006 11.029.000 10.25%
2007 14.348.000 23.13%
2008 13.900.000 -3.22%
2009 14.898.000 6.7%
2010 16.040.000 7.12%
2011 20.422.000 21.46%
2012 21.471.000 4.89%
2013 24.469.000 12.25%
2014 28.228.000 13.32%
2015 36.916.000 23.53%
2017 33.911.000 -8.86%
2018 36.716.000 7.64%
2019 38.489.000 4.61%
2020 38.600.000 0.29%
2021 43.812.000 11.9%
2022 0 0%
2023 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

ImmunoGen, Inc. EBITDA
Year EBITDA Growth
1988 -4.900.000
1989 -7.500.000 34.67%
1990 -7.500.000 0%
1991 -14.000.000 46.43%
1992 -16.800.000 16.67%
1993 -21.500.000 21.86%
1994 -15.900.000 -35.22%
1995 -3.000.000 -430%
1996 -7.900.000 62.03%
1997 -6.600.000 -19.7%
1998 -3.800.000 -73.68%
1999 -366.607 -936.53%
2000 -15.663.903 97.66%
2001 -20.568.350 23.84%
2002 -25.424.924 19.1%
2003 -8.589.219 -196.01%
2004 -10.527.000 18.41%
2005 -18.993.000 44.57%
2006 -22.347.000 15.01%
2007 -32.298.000 30.81%
2008 -26.600.000 -21.42%
2009 -46.455.000 42.74%
2010 -57.165.000 18.74%
2011 -68.562.000 16.62%
2012 -68.494.000 -0.1%
2013 -66.977.000 -2.26%
2014 -49.858.000 -34.34%
2015 -119.685.000 58.34%
2017 -55.596.000 -115.28%
2018 -153.454.000 63.77%
2019 -65.726.000 -133.48%
2020 -19.683.000 -233.92%
2021 -126.153.000 84.4%
2022 -217.546.000 42.01%
2023 122.544.000 277.52%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

ImmunoGen, Inc. Gross Profit
Year Gross Profit Growth
1988 -3.900.000
1989 -6.100.000 36.07%
1990 -6.100.000 0%
1991 4.000.000 252.5%
1992 3.400.000 -17.65%
1993 -17.000.000 120%
1994 -12.900.000 -31.78%
1995 6.500.000 298.46%
1996 1.900.000 -242.11%
1997 1.700.000 -11.76%
1998 4.200.000 59.52%
1999 11.643.952 63.93%
2000 3.882.313 -199.92%
2001 2.541.922 -52.73%
2002 4.793.891 46.98%
2003 20.296.938 76.38%
2004 26.482.000 23.36%
2005 29.420.000 9.99%
2006 34.640.000 15.07%
2007 40.249.000 13.94%
2008 27.988.000 -43.81%
2009 13.943.000 -100.73%
2010 19.305.000 27.78%
2011 16.357.000 -18.02%
2012 -51.538.000 131.74%
2013 -47.062.000 -9.51%
2014 -26.227.000 -79.44%
2015 -88.075.000 70.22%
2017 -24.292.000 -262.57%
2018 -120.070.000 79.77%
2019 -32.251.000 -272.3%
2020 17.707.000 282.14%
2021 69.856.000 74.65%
2022 108.606.000 35.68%
2023 445.080.000 75.6%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

ImmunoGen, Inc. Net Profit
Year Net Profit Growth
1988 -5.300.000
1989 -8.300.000 36.14%
1990 -8.800.000 5.68%
1991 -15.300.000 42.48%
1992 -18.600.000 17.74%
1993 -23.700.000 21.52%
1994 -19.900.000 -19.1%
1995 -16.500.000 -20.61%
1996 -9.000.000 -83.33%
1997 -7.600.000 -18.42%
1998 -4.100.000 -85.37%
1999 -237.560 -1625.88%
2000 -15.290.682 98.45%
2001 -14.629.839 -4.52%
2002 -19.982.308 26.79%
2003 -5.916.741 -237.72%
2004 -10.951.000 45.97%
2005 -17.834.000 38.59%
2006 -18.987.000 6.07%
2007 -32.020.000 40.7%
2008 -31.937.000 -0.26%
2009 -50.912.000 37.27%
2010 -58.274.000 12.63%
2011 -73.319.000 20.52%
2012 -72.811.000 -0.7%
2013 -71.364.000 -2.03%
2014 -60.739.000 -17.49%
2015 -144.817.000 58.06%
2017 -96.012.000 -50.83%
2018 -164.155.000 41.51%
2019 -122.093.000 -34.45%
2020 -66.683.000 -83.09%
2021 -149.356.000 55.35%
2022 -222.929.000 33%
2023 122.992.000 281.25%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

ImmunoGen, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1988 -3
1989 -1 -200%
1990 -1 0%
1991 -2 0%
1992 -2 0%
1993 -2 50%
1994 -2 -100%
1995 -1 0%
1996 -1 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 -1 0%
2008 -1 0%
2009 -1 0%
2010 -1 0%
2011 -1 0%
2012 -1 0%
2013 -1 0%
2014 -1 0%
2015 -2 100%
2017 -1 0%
2018 -1 100%
2019 -1 0%
2020 0 0%
2021 -1 0%
2022 -1 100%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

ImmunoGen, Inc. Free Cashflow
Year Free Cashflow Growth
1988 -5.400.000
1989 -9.100.000 40.66%
1990 -9.100.000 0%
1991 -15.800.000 42.41%
1992 -23.600.000 33.05%
1993 -29.100.000 18.9%
1994 -17.200.000 -69.19%
1995 -8.600.000 -100%
1996 -8.100.000 -6.17%
1997 -6.000.000 -35%
1998 -3.600.000 -66.67%
1999 1.945.252 285.07%
2000 -8.766.193 122.19%
2001 -20.266.737 56.75%
2002 -25.542.493 20.65%
2003 -6.971.837 -266.37%
2004 -4.500.000 -54.93%
2005 -16.407.000 72.57%
2006 -17.763.000 7.63%
2007 -38.149.000 53.44%
2008 -15.230.000 -150.49%
2009 -42.118.000 63.84%
2010 -10.018.000 -320.42%
2011 -37.196.000 73.07%
2012 -64.069.000 41.94%
2013 -61.834.000 -3.61%
2014 -62.716.000 1.41%
2015 -134.852.000 53.49%
2017 6.529.000 2165.43%
2018 -171.668.000 103.8%
2019 -91.212.000 -88.21%
2020 -79.537.000 -14.68%
2021 -170.850.000 53.45%
2022 -231.166.000 26.09%
2023 1.416.000 16425.28%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

ImmunoGen, Inc. Operating Cashflow
Year Operating Cashflow Growth
1988 -4.700.000
1989 -6.800.000 30.88%
1990 -8.300.000 18.07%
1991 -13.600.000 38.97%
1992 -15.400.000 11.69%
1993 -21.500.000 28.37%
1994 -16.700.000 -28.74%
1995 -8.600.000 -94.19%
1996 -8.000.000 -7.5%
1997 -6.000.000 -33.33%
1998 -3.500.000 -71.43%
1999 2.369.173 247.73%
2000 -6.414.283 136.94%
2001 -16.002.681 59.92%
2002 -21.883.714 26.87%
2003 -5.015.855 -336.29%
2004 -2.065.000 -142.9%
2005 -14.281.000 85.54%
2006 -15.781.000 9.51%
2007 -20.149.000 21.68%
2008 -13.334.000 -51.11%
2009 -40.584.000 67.14%
2010 -7.989.000 -408%
2011 -34.288.000 76.7%
2012 -60.299.000 43.14%
2013 -53.650.000 -12.39%
2014 -55.291.000 2.97%
2015 -124.476.000 55.58%
2017 7.645.000 1728.2%
2018 -166.422.000 104.59%
2019 -88.367.000 -88.33%
2020 -78.620.000 -12.4%
2021 -169.416.000 53.59%
2022 -229.802.000 26.28%
2023 2.770.000 8396.1%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

ImmunoGen, Inc. Capital Expenditure
Year Capital Expenditure Growth
1988 700.000
1989 2.300.000 69.57%
1990 800.000 -187.5%
1991 2.200.000 63.64%
1992 8.200.000 73.17%
1993 7.600.000 -7.89%
1994 500.000 -1420%
1995 0 0%
1996 100.000 100%
1997 0 0%
1998 100.000 100%
1999 423.921 76.41%
2000 2.351.910 81.98%
2001 4.264.056 44.84%
2002 3.658.779 -16.54%
2003 1.955.982 -87.06%
2004 2.435.000 19.67%
2005 2.126.000 -14.53%
2006 1.982.000 -7.27%
2007 18.000.000 88.99%
2008 1.896.000 -849.37%
2009 1.534.000 -23.6%
2010 2.029.000 24.4%
2011 2.908.000 30.23%
2012 3.770.000 22.86%
2013 8.184.000 53.93%
2014 7.425.000 -10.22%
2015 10.376.000 28.44%
2017 1.116.000 -829.75%
2018 5.246.000 78.73%
2019 2.845.000 -84.39%
2020 917.000 -210.25%
2021 1.434.000 36.05%
2022 1.364.000 -5.13%
2023 1.354.000 -0.74%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

ImmunoGen, Inc. Equity
Year Equity Growth
1988 7.000.000
1989 12.200.000 42.62%
1990 42.000.000 70.95%
1991 59.100.000 28.93%
1992 40.500.000 -45.93%
1993 30.000.000 -35%
1994 10.100.000 -197.03%
1995 2.700.000 -274.07%
1996 4.500.000 40%
1997 4.300.000 -4.65%
1998 5.300.000 18.87%
1999 15.367.957 65.51%
2000 142.446.766 89.21%
2001 134.215.113 -6.13%
2002 102.679.130 -30.71%
2003 97.136.881 -5.71%
2004 86.842.000 -11.85%
2005 72.350.000 -20.03%
2006 58.401.000 -23.88%
2007 55.299.000 -5.61%
2008 66.857.000 17.29%
2009 102.048.000 34.48%
2010 139.969.000 27.09%
2011 83.890.000 -66.85%
2012 121.847.000 31.15%
2013 75.699.000 -60.96%
2014 35.104.000 -115.64%
2015 -82.304.000 142.65%
2017 -17.895.000 -359.93%
2018 11.942.000 249.85%
2019 -76.121.000 115.69%
2020 89.570.000 184.98%
2021 325.586.000 72.49%
2022 155.826.000 -108.94%
2023 561.596.000 72.25%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

ImmunoGen, Inc. Assets
Year Assets Growth
1988 9.100.000
1989 15.100.000 39.74%
1990 44.400.000 65.99%
1991 62.000.000 28.39%
1992 46.500.000 -33.33%
1993 38.400.000 -21.09%
1994 17.000.000 -125.88%
1995 8.500.000 -100%
1996 6.300.000 -34.92%
1997 5.900.000 -6.78%
1998 7.200.000 18.06%
1999 19.344.281 62.78%
2000 159.160.720 87.85%
2001 152.155.842 -4.6%
2002 118.031.938 -28.91%
2003 122.630.364 3.75%
2004 110.132.000 -11.35%
2005 94.128.000 -17%
2006 80.421.000 -17.04%
2007 83.338.000 3.5%
2008 100.704.000 17.24%
2009 137.208.000 26.6%
2010 217.641.000 36.96%
2011 180.308.000 -20.71%
2012 213.596.000 15.58%
2013 165.318.000 -29.2%
2014 313.823.000 47.32%
2015 287.085.000 -9.31%
2017 294.676.000 2.58%
2018 295.751.000 0.36%
2019 235.662.000 -25.5%
2020 355.072.000 33.63%
2021 525.765.000 32.47%
2022 348.936.000 -50.68%
2023 822.101.000 57.56%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

ImmunoGen, Inc. Liabilities
Year Liabilities Growth
1988 2.100.000
1989 2.900.000 27.59%
1990 2.400.000 -20.83%
1991 2.900.000 17.24%
1992 6.000.000 51.67%
1993 8.400.000 28.57%
1994 6.900.000 -21.74%
1995 5.800.000 -18.97%
1996 1.800.000 -222.22%
1997 1.600.000 -12.5%
1998 1.900.000 15.79%
1999 3.976.324 52.22%
2000 16.713.954 76.21%
2001 17.940.729 6.84%
2002 15.352.808 -16.86%
2003 25.493.483 39.78%
2004 23.290.000 -9.46%
2005 21.778.000 -6.94%
2006 22.020.000 1.1%
2007 28.039.000 21.47%
2008 33.847.000 17.16%
2009 35.160.000 3.73%
2010 77.672.000 54.73%
2011 96.418.000 19.44%
2012 91.749.000 -5.09%
2013 89.619.000 -2.38%
2014 278.719.000 67.85%
2015 369.389.000 24.55%
2017 312.571.000 -18.18%
2018 283.809.000 -10.13%
2019 311.783.000 8.97%
2020 265.502.000 -17.43%
2021 200.179.000 -32.63%
2022 193.110.000 -3.66%
2023 260.505.000 25.87%

ImmunoGen, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
1.14
Net Income per Share
-0.29
Price to Earning Ratio
-19.65x
Price To Sales Ratio
4.35x
POCF Ratio
-7.25
PFCF Ratio
-6.26
Price to Book Ratio
2.56
EV to Sales
2.49
EV Over EBITDA
-10.45
EV to Operating CashFlow
-3.62
EV to FreeCashFlow
-3.59
Earnings Yield
-0.05
FreeCashFlow Yield
-0.16
Market Cap
1,25 Bil.
Enterprise Value
0,72 Bil.
Graham Number
3.79
Graham NetNet
1.76

Income Statement Metrics

Net Income per Share
-0.29
Income Quality
2.69
ROE
-0.22
Return On Assets
-0.09
Return On Capital Employed
-0.11
Net Income per EBT
1.01
EBT Per Ebit
0.96
Ebit per Revenue
-0.26
Effective Tax Rate
-0.01

Margins

Sales, General, & Administrative to Revenue
0.13
Research & Developement to Revenue
0.72
Stock Based Compensation to Revenue
0.12
Gross Profit Margin
0.99
Operating Profit Margin
-0.26
Pretax Profit Margin
-0.25
Net Profit Margin
-0.25

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.78
Free CashFlow per Share
-0.79
Capex to Operating CashFlow
0.01
Capex to Revenue
-0.01
Capex to Depreciation
-1.09
Return on Invested Capital
-0.12
Return on Tangible Assets
-0.09
Days Sales Outstanding
165.86
Days Payables Outstanding
2346.44
Days of Inventory on Hand
518.8
Receivables Turnover
2.2
Payables Turnover
0.16
Inventory Turnover
0.7
Capex per Share
-0.01

Balance Sheet

Cash per Share
2,39
Book Value per Share
2,22
Tangible Book Value per Share
2.22
Shareholders Equity per Share
2.22
Interest Debt per Share
0.32
Debt to Equity
0.14
Debt to Assets
0.09
Net Debt to EBITDA
7.77
Current Ratio
5.47
Tangible Asset Value
0,56 Bil.
Net Current Asset Value
0,48 Bil.
Invested Capital
0.14
Working Capital
0,60 Bil.
Intangibles to Total Assets
0
Average Receivables
0,11 Bil.
Average Payables
0,02 Bil.
Average Inventory
4364000
Debt to Market Cap
0.06

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

ImmunoGen, Inc. Dividends
Year Dividends Growth

ImmunoGen, Inc. Profile

About ImmunoGen, Inc.

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

CEO
Mr. Mark Joseph Enyedy
Employee
277
Address
830 Winter Street
Waltham, 02451-1477

ImmunoGen, Inc. Executives & BODs

ImmunoGen, Inc. Executives & BODs
# Name Age
1 Anabel Chan
Head of Investor Relations
70
2 Ms. Courtney O'Konek
Senior Director of Corporate Communications & Investor Relations
70
3 Dr. Theresa G. Wingrove
Senior Vice President of Regulatory Affairs & Quality
70
4 Mr. Daniel S. Char J.D.
Senior Vice President, Chief Legal Officer & Secretary
70
5 Ms. Lauren A. White M.B.A.
Senior Vice President & Chief Financial Officer
70
6 Ms. Isabel Kalofonos
Senior Vice President & Chief Commercial Officer
70
7 Mr. Mark Joseph Enyedy
President, Chief Executive Officer & Director
70
8 Dr. Michael J. Vasconcelles M.D., Ph.D.
Chief Medical Officer
70
9 Ms. Audrey Bergan
Senior Vice President & Chief HR Officer
70

ImmunoGen, Inc. Competitors